Effect of Nigella Sativa oil versus metformin on glycemic control and biochemical parameters of newly diagnosed type 2 diabetes mellitus patients

Endocrine ◽  
2019 ◽  
Vol 65 (2) ◽  
pp. 286-294 ◽  
Author(s):  
Hebatallah Ahmed Mohamed Moustafa ◽  
Lamia Mohamed El Wakeel ◽  
Mohamed Reda Halawa ◽  
Nagwa Ali Sabri ◽  
Alshaymaa Zaki El-Bahy ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Glycemic Control ◽  
Biochemical Parameters ◽  
Nigella Sativa ◽  
Newly Diagnosed ◽  
Nigella Sativa Oil

scholarly journals Dose-dependent relationship between serum metformin levels and glycemic control, insulin resistance and leptin levels in females newly diagnosed with type 2 diabetes mellitus

2012 ◽  
Vol 02 (02) ◽  
pp. 179-185 ◽  
Author(s):  
Kadhim Ali Kadhim ◽  
Dowser Khalil Ismael ◽  
Ban Hoshi Khalaf ◽  
Khalid Ibrahim Hussein ◽  
Munaf Hashim Zalzala ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Insulin Resistance ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Glycemic Control ◽  
Newly Diagnosed ◽  
Dependent Relationship ◽  
Dose Dependent

Effect of Nigella sativa oil supplement on risk factors for cardiovascular diseases in patients with type 2 diabetes mellitus

2020 ◽  
Vol 34 (10) ◽  
pp. 2706-2711
Author(s):  
Akram Kooshki ◽  
Tahereh Tofighiyan ◽  
Neda Rastgoo ◽  
Mohammad Hassan Rakhshani ◽  
Mohammad Miri
Keyword(s):  
Diabetes Mellitus ◽  
Risk Factors ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cardiovascular Diseases ◽  
Nigella Sativa ◽  
Nigella Sativa Oil

scholarly journals Nigella sativa Improves Glycemic Control and Ameliorates Oxidative Stress in Patients with Type 2 Diabetes Mellitus: Placebo Controlled Participant Blinded Clinical Trial

PLoS ONE ◽  
2015 ◽  
Vol 10 (2) ◽  
pp. e0113486 ◽  
Author(s):  
Huda Kaatabi ◽  
Abdullah Omar Bamosa ◽  
Ahmed Badar ◽  
Abdulmohsen Al-Elq ◽  
Bodour Abou-Hozaifa ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Clinical Trial ◽  
Type 2 Diabetes Mellitus ◽  
Glycemic Control ◽  
Nigella Sativa

scholarly journals Variability in the Therapeutic Response of Metformin treatment in patients with type 2 diabetes Mellitus

2019 ◽  
Vol 35 (1) ◽  
Author(s):  
Maryam Rashid ◽  
Muhammad Shahzad ◽  
Saqib Mahmood ◽  
Khurshid Khan
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Glycemic Control ◽  
Therapeutic Response ◽  
Signs And Symptoms ◽  
Metformin Treatment ◽  
Newly Diagnosed ◽  
Baseline Bmi

Objective: To assess the glycemic response of metformin in patients with Type-2 Diabetes Mellitus (T2DM) as well as to see its association with reductions in BMI and GIT intolerance. Methods: This Quasi, Experimental study was conducted at Jinnah-Allama Iqbal Institute of Diabetes and Endocrinology (JAIDE) Jinnah Hospital, Lahore from 1st March 2016 to 30th September 2016. Newly diagnosed T2DM patients were given metformin for duration of three months and later on they were categorized into Responders and Non-Responders on the basis of HbA1c (A1C) reductions, which were estimated by Hemoglobin (A1C) analyzer (TD4611A TAIDoc Tech. Taiwan) through photometry. Similarly, baseline BMI and BMI after three months therapy with metformin was also recorded. Results: Among total of 200 patients, 40.5% of the patients were classified as Non-Responders whereas; 59.5% of the patients as Responders. The baseline BMI (26.09 kg/m2) was also decreased significantly after metformin therapy (25.40 kg/m2). It was found that metformin reduced the A1C in all the patients. However, the glycemic control was much better in patients with higher baseline A1C (1.13% ± 0.08) as compared to lower baseline levels (0.61% ± 0.07). Regarding GIT intolerance, 140 patients lacked the symptoms, out of which 60.7% were responders and 39.3% were non-responders. Conclusions: Metformin lead to improvement in glycemic control in 59.5% of newly diagnosed T2DM patients after taking metformin for three months but in 40.5% it did not which may be because of combined effects of various gene polymorphisms and their interaction with non-genetic factors. Metformin reduced the BMI in all the patients; however, BMI lowering activity of metformin was same regardless of its effect on HbA1C. Moreover, the signs and symptoms of GIT intolerance did not differ between the two groups. How to cite this:Rashid M, Shahzad M, Mahmood S, Khan K. Variability in the therapeutic response of Metformin treatment in patients with type 2 diabetes mellitus. Pak J Med Sci. 2019;35(1):71-76. doi: https://doi.org/10.12669/pjms.35.1.100 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

scholarly journals EFFECTS OF A COMBINATION THERAPY WITH ATORVASTATIN AND METFORMIN ON THE GLYCEMIC CONTROL AND ADIPOSITY INDICES IN NEWLY DIAGNOSED OVERWEIGHT PATIENTS WITH TYPE 2 DIABETES MELLITUS: A PILOT STUDY

2018 ◽  
Vol 11 (12) ◽  
pp. 209
Author(s):  
Samer Shukur Mohammed ◽  
Wael Waleed Mustafa ◽  
Saad Abdulrahman Hussain
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Glycemic Control ◽  
Lipid Profile ◽  
Visceral Adiposity Index ◽  
Newly Diagnosed ◽  
Adiposity Index ◽  
Adiposity Indices

Objective: In many type 2 diabetes mellitus (T2DM) patients, metformin is prescribed concomitantly with hypolipidemic agents, particularly statins. Meanwhile, variability in response to metformin is one of the most important problems in the efficacy of this combination. The present study aims to evaluate the effect of adding atorvastatin with metformin on the glycemic control, adiposity indices, and lipid profile of overweight patients newly diagnosed with type T2DM.Methods: A total of 50 overweight patients with T2DM were allocated into two groups, the first one received 850 mg/day of sustained release metformin and the second group received 10 mg/day atorvastatin in addition to the metformin. The patients were followed for 90 days through evaluating fasting serum glucose (FSG), glycated hemoglobin (HbA1c), body mass index (BMI), visceral adiposity index (VAI), and the lipid profile at baseline and after 90 days. In addition, the safety of the protocol was monitored through the evaluation of the renal and liver functions.Results: HbA1c, FSG, BMI, and VAI values were significantly decreased in both treatment groups compared with baseline. Meanwhile, the combination improves all the lipid profile components with respect to the baseline. No significant differences reported between the two groups regarding all the measured parameters. The addition of atorvastatin produced a slight but significant negative impact on the renal and liver functions.Conclusion: Addition of 10 mg/day atorvastatin with metformin in the treatment of newly diagnosed T2DM overweight patients did not produce significant improvement in glycemic control, adiposity index, and lipid profile compared with the use of metformin alone.

Sign in / Sign up

Export Citation Format

Share Document